Newron Pharmaceuticals SpA has held initial discussions with potential partners about licensing an experimental drug to treat schizophrenia, a mental health condition with no cure. “We see a good chance of a licensing deal in the second half of the year,” Chief Executive Officer Stefan Weber said in a telephone interview late on Tuesday.
Category: Eli Lilly
5 Expensive Drugs That Could End Up in Trump’s Crosshairs
Donald Trump’s taking aim at drug companies that have increasingly found themselves in the hot seat because of sky-high drug price increases in the past. Last week, Trump likened the industry’s history of price hikes as akin to “getting away with murder,” and he hinted that significant changes to how government programs pay for medicine are afoot.